aldeyra.com (ALDX) Year-over-year earnings per share growth for the last twelve months

Official company branding of Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics (ALDX) is competing for the ophthalmology market, where access is restricted by patents on anti-inflammatory molecules. This quarterly earnings per share chart demonstrates the asset's dynamics, while 51.10 reflects the metric's latest value. Growth depends on FDA approval of reproxalap and new developments. Currently, commercialization is blocked pending the regulator's final verdict, despite investor interest.

Aldeyra Therapeutics, Inc. (ALDX) - Quarterly EPS earnings growth from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for aldeyra.com (ALDX)

- share price and expert price forecast:
Comprehensive company analysis:Aldeyra Therapeutics Inc., ALDX
Flagship merchandise of Aldeyra Therapeutics

Earnings per share dynamics determine the fundamental stability of the business over the long term. This metric captures the percentage change in quarterly net income, stripping the financial result of market volatility. By assessing quarterly EPS growth, an investor tracks the pace of asset capitalization. For Aldeyra Therapeutics (ALDX), this indicator reflects the efficiency of implementing automated molecule screening systems. The robotization of ophthalmological research should convert into lower costs and increased bottom-line profit.

Analysis of competing companies

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months glaukos.com|Apellis Pharmaceuticals (APLS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth BLTE|OCUL - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth HROW (Harrow Inc)|Year-over-year net earnings per share change for the last twelve months Viridian Corp (VRDN)|LENZ - Year-over-year earnings per share growth for the last twelve months|Oculis - Year-over-year earnings per share growth rate for the last twelve months|EyePoint Pharmaceuticals (EYPT) - Year-over-year earnings per share growth for the last twelve months|Kodiak Sciences Inc (KOD) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months KALA|IRD - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com (OKYO)|Quarterly EPS earnings growth Adverum Biotechnologies Inc. (ADVM)|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)